Study title: Efficacy and safety of Symbicort® (budesonide/formoterol 80/4.5 µg, 2 inhal. b.i.d.) compared to Pulmicort® (budesonide 100 µg, 2 inhal. b.i.d.) and Pulmicort (budesonide 100 µg, 2 inhal. b.i.d.) plus Oxis® (formoterol 4.5 µg, 2 inhal. b.i.d.) all delivered via Turbuhaler® in steroid using asthmatic children. A double-blind, double-dummy, randomised, parallel-group, phase III, multicentre 12-week study.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases [C08] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: BUDESONIDE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: SD-039-0688 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |